Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients

被引:0
作者
Ji-no, K
Tanimizu, M
Hyodo, I
Nishikawa, Y
Hosokawa, Y
Endo, H
Doi, T
Mandai, K
Ishitsuka, H
机构
[1] Natl Shikoku Canc Ctr Hosp, Dept Clin Res, Matsuyama, Ehime 790, Japan
[2] Nippon Roche Res Ctr, Kamakura, Kanagawa 247, Japan
关键词
angiogenic factor; platelet-derived endothelial cell growth factor; hepatocellular carcinoma; tumor marker; immunohistology;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Platelet-derived endothelial cell growth factor (PD-ECGF) is an angiogenic factor that is expressed in various cancer tissues. Little is known regarding plasma PD-ECGF levels in patients with chronic liver disease such as chronic hepatitis (CII), cirrhosis, and hepatocellular carcinoma (HCC) with cirrhosis. The expression of PD-ECGF in HCC tissues also remains to be clarified. METHODS, Plasma PD-ECGF levels in patients with chronic liver disease were determined with an enzyme-linked immunoadsorbent assay system using the mouse monoclonal antibodies specific to PD-ECGF. These were cross-sectionally compared among groups of normal persons, CH, cirrhosis, and HCC patients. The HCC patients were classified Into two groups based on TNM stage: early and advanced stage disease groups. PD-ECGF expressions in HCC tissues were immunohistologically examined RESULTS, The plasma PD-ECGF levels from the normal individuals and those with CH, cirrhosis, and HCC specimens were 4.2 +/- 0.5, 4.3 +/- 0.6, 4.6 +/- 1.1, and 6.0 +/- 2.5 U/mL, respectively. The plasma PD-ECGF concentration was highest in HCC [P < 0.05], No significant difference was found among the normal subjects, CH, and cirrhosis specimens. Plasma PD-ECGF concentrations were significantly higher in the advanced stage disease HCC group compared with, the early stage disease-group (6.75 +/- 2.62 U/mL vs. 4.19 +/- 0.34 U/mL) (P < 0.05). Immunohistochemical expression of PD-ECGF in HCC cells increased significantly compared with normal liver cells (P < 0.05). CONCLUSIONS, Circulating PD-ECGF plasma level might be a new tumor marker for progression in patients with HCC. Immunohistological findings correspond to elevation of the plasma PD-ECGF in HCC patients. It is possible that increased production of PD-ECGF in HCC cells causes abundant neovascularization. (C) 1998 American Cancer Society.
引用
收藏
页码:1260 / 1267
页数:8
相关论文
共 24 条
  • [11] Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma
    Maeda, K
    Chung, YS
    Ogawa, Y
    Takatsuka, S
    Kang, SM
    Ogawa, M
    Sawada, T
    Onoda, N
    Kato, Y
    Sowa, M
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (08) : 884 - 888
  • [12] MIYADERA K, 1995, CANCER RES, V55, P1687
  • [13] Nishida M, 1996, BIOL PHARM BULL, V19, P1407
  • [14] PAULY JL, 1978, P SOC EXP BIOL MED, V157, P262
  • [15] IDENTIFICATION AND COMPARATIVE ANALYSIS OF THYMIDINE PHOSPHORYLASE IN PLASMA OF HEALTHY SUBJECTS AND CANCER-PATIENTS
    PAULY, JL
    SCHULLER, MG
    ZELCER, AA
    KIRSS, TA
    GORE, SS
    GERMAIN, MJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 58 (06) : 1587 - 1590
  • [16] ASSOCIATION OF OVARIAN MALIGNANCY WITH EXPRESSION OF PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR
    REYNOLDS, K
    FARZANEH, F
    COLLINS, WP
    CAMPBELL, S
    BOURNE, TH
    LAWTON, F
    MOGHADDAM, A
    HARRIS, AL
    BICKNELL, R
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (16) : 1234 - 1238
  • [17] SCHAFFNER F, 1963, GASTROENTEROLOGY, V44, P239
  • [18] TRANSFORMING GROWTH FACTOR-ALPHA - A MORE POTENT ANGIOGENIC MEDIATOR THAN EPIDERMAL GROWTH-FACTOR
    SCHREIBER, AB
    WINKLER, ME
    DERYNCK, R
    [J]. SCIENCE, 1986, 232 (4755) : 1250 - 1253
  • [19] SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO
  • [20] 2-T